The establishment of six years of Berry and Kang, from the beginning of the creation of a non-invasive prenatal genetic testing market in the East, in 2011, won the Grand Alliance capital A round of financing $17 million 800 thousand, in the middle of 2013, and received a $25 million B round of financing, led by Qiming venture investment. Subsequently, Berry held in 2014 to 2015 of non-invasive prenatal genetic testing commercial opportunity to become a leader after noninvasive prenatal genetic testing field of bgi. In 2016, Berry discovered the new progress is the backdoor landing A shares.

“Small company merger” or will become the precise medical mainstream business model

In May 31, 2016, the relevant media reports, the Irish biopharmaceutical company (JAZZ), pharmaceutical will be $1 billion 500 million acquisition of Celator pharmaceuticals (CPXX), the purchase price is about two times of Celator pharmaceutical market. Celator pharmaceutical stocks in 2016 is fully deserve star, after the company suspended March 14th announcement that the company’s drug VYXEOS by phase three clinical confirmed that acute myeloid leukemia (AML) in high-risk patients (grade two) overall survival rate increased significantly. The company shares resume trading day rose 400%, after continued to rise. As of May 31st closing price of $17.53. 3 months rose nearly 10 times already, led the NASDAQ market.

The medical merger has gradually become the main way for global capital exit. With the vigorous development of the medical field of entrepreneurial Israel as an example, startups grow to a certain extent, many choose to exit the merger case. Share investment investment investment investment enjoy Introduction Manager Wu Han, 2005 to 2014, a total of 62 Israeli medical health industry company mergers and acquisitions, the average operation time of medical and health industry companies for 12.3 years, from the first financing to exit the merger took an average of 8.68 years. However, this is mainly because the bio pharmaceutical and biotechnology and other segments of elongated capital return period, ordinary medical enterprises to invest in a relatively short period.

In the China capital market, mergers and acquisitions of listed companies into the precise medical case already exists, mergers and acquisitions also increased the story space for listed companies. In October 2015, a new day constant announcement, to 1 billion 566 million yuan acquisition boyalife 80% shares, boyalife became a subsidiary, constant new day in November 23, 2015, the resolution adopted by the general meeting of shareholders, a new day constant to take into the field of biology and medicine.

In May 11, 2015, the number of new announcement that the company intends to target specific non-public offering of shares to acquire three economic, medical and biological Oh Seoul crystal bio 100% stake, and to 13.20 yuan / share to 3 specific object given by 13 million 710 thousand shares to raise matching funds 154 million 600 thousand yuan for the underlying asset integration, capital arrangement. Xinkaiyuan also through this acquisition into the tumor early diagnosis, molecular diagnosis and gene sequencing of in vitro diagnostic services.

At the same time, the listed companies will choose to set up the way of mergers and acquisitions fund cut precision medical, choose investment targets in the global scope. In February 2016, the medical Dunlop announcement that intends to use the self financing of $95 million with the Yantai people and De Yuan equity investment management center (limited partnership) jointly set up a total size of not more than $100 million in global precision medical innovation investment fund. At present, the fund has invested in the field of liquid biopsy, the American Quanterix company, invested $11 million in the D round of financing way to increase its stake of 5.35%.

Will the possible acquisition of startups between